Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro
AUTOR(ES)
Souza, Claudia Teresa Vieira de, Hökerberg, Yara Hahr Marques, Pacheco, Sandro Javier Bedoya, Rolla, Valéria Cavalcanti, Passos, Sonia Regina Lambert
FONTE
Memórias do Instituto Oswaldo Cruz
DATA DE PUBLICAÇÃO
2009-05
RESUMO
The clinical and epidemiological characteristics, adverse events, treatment adherence and effectiveness of isoniazid chemoprophylaxis were analyzed in a cohort of 138 tuberculosis/HIV-coinfected patients. An open, non-randomized, pragmatic prophylactic trial was conducted on adult patients with a normal chest X-ray and positive tuberculin skin test (> 5 mm) who received isoniazid chemoprophylaxis (300 mg/day) for six months. The mean of follow up was 2.8 years (SD 1.3). Adherence to chemoprophylaxis was 87.7% (121/138). Only one patient presented tuberculosis after the end of chemoprophylaxis, corresponding to 0.3 cases per 100 persons per year. The relative risk of some adverse effects was 4.6 times higher (95% CI: 1.9-11.5) in patients with positive anti-HCV serology (4/9, 44.4%) compared to those with negative serology (12/129, 9.6%) (p = 0.002). This study provides evidence regarding the effectiveness and safety of a short and self-administered isoniazid regimen. We recommend the implementation of this routine by health service practitioners.
Documentos Relacionados
- Potential overestimation of HIV-1 sub-subtype F1 circulation in Rio de Janeiro, Brazil
- Diphtheria Antibodies and T lymphocyte Counts in Patients Infected with HIV-1
- Identificação de epitopos da protease de HIV-1 alvos de respostas de células T CD4+ em pacientes infectados pelo HIV-1
- Lipid profile of HIV-1 infected patients under highly active antiretroviral therapy
- Hospitalization rates, length of stay and in-hospital mortality in a cohort of HIV infected patients from Rio de Janeiro, Brazil